Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy
about
Chemotherapy options in castration-resistant prostate cancerBiomarkers and Surrogate Endpoints: Lessons Learned From Glaucoma.End points of clinical trials in metastatic castration-resistant prostate cancer: A systematic reviewChange in PSA velocity is a predictor of overall survival in men with biochemically-recurrent prostate cancer treated with nonhormonal agents: combined analysis of four phase-2 trials.Disease Progression/Clinical Outcome Model for Castration-Resistant Prostate Cancer in Patients Treated With EribulinAssociation of early PSA decline and time to PSA progression in abiraterone acetate-treated metastatic castration-resistant prostate cancer; a post-hoc analysis of Japanese phase 2 trials.Biomarkers for the Management of Castration-Resistant Prostate Cancer: We Are Not There Yet.Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer.Very Early PSA Response to Abiraterone in mCRPC Patients: A Novel Prognostic Factor Predicting Overall SurvivalHigh Dimensional Variable Selection with Error ControlRadiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer.Prostate cancer: measuring PSA.Circulating tumour cells-monitoring treatment response in prostate cancer.Switching and withdrawing hormonal agents for castration-resistant prostate cancer.Statistical evaluation of surrogate endpoints with examples from cancer clinical trials.Non-Mono-Exponential Analysis of Diffusion-Weighted Imaging for Treatment Monitoring in Prostate Cancer Bone Metastases.Efficacy and safety of post-docetaxel therapies in metastatic castration-resistant prostate cancer: a systematic review of the literature.Managing Metastatic Castration-Resistant Prostate Cancer in the Pre-chemotherapy Setting: A Changing Approach in the Era of New Targeted Agents.Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421.Serial 18F-choline-PET imaging in patients receiving enzalutamide for metastatic castration-resistant prostate cancer: response assessment and imaging biomarkers.Potential value of rapid prostate-specific antigen decline in identifying primary resistance to abiraterone acetate and enzalutamide.Docetaxel rechallenge after an initial good response in patients with metastatic castration-resistant prostate cancer.Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxelPSA declines and survival in patients with metastatic castration-resistant prostate cancer treated with enzalutamide: A retrospective case-report study.Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate CancerPSA response to cabazitaxel is associated with improved progression-free survival in metastatic castration-resistant prostate cancer: the non-interventional QoLiTime study.Mathematical modeling of efficacy and safety for anticancer drugs clinical development.Diffusion-weighted Imaging as a Treatment Response Biomarker for Evaluating Bone Metastases in Prostate Cancer: A Pilot Study.Sequential therapies in castration-resistant prostate cancer.Contemporary molecular tests for prognosis and treatment guidance for castration-resistant prostate cancer.A mini-review of quality of life as an outcome in prostate cancer trials: patient-centered approaches are needed to propose appropriate treatments on behalf of patients.Impact of early changes in serum biomarkers following androgen deprivation therapy on clinical outcomes in metastatic hormone-sensitive prostate cancer.Quick efficacy seeking trial (QuEST1): a novel combination immunotherapy study designed for rapid clinical signal assessment metastatic castration-resistant prostate cancer
P2860
Q28078477-F711D0B0-F40A-4A50-8666-8026472208E1Q33756518-9A9508D9-A7AB-4CBF-B3B6-5686333A6327Q34367585-474EEE67-C452-43D4-A971-DB69FF187110Q35070443-6BD9804D-373C-443B-A928-A4279BB37042Q35979551-FD8C27CE-6A8D-467B-9E84-3E11F79A42B3Q36045735-DA7895B3-BAB4-42B0-95A8-0B75D12757E1Q36407003-43F4F007-E5F0-4DC8-89B1-8C39ACCE83EBQ36410270-510860EC-3C44-4DB4-85F4-27053B59439CQ36909750-919AA695-4857-45C5-A432-2953EFDC8F96Q37212655-F6B11792-33A1-414E-9229-015364069E85Q38168261-19D67496-4BEE-4C19-9537-74FC546B132DQ38210857-2441F2E4-080C-4FFC-805D-52D07835B2C9Q38211361-7A1532DE-6532-455F-B004-BBB6F8EBD7EBQ38309205-AAA3C6DE-CFF2-437B-81CB-3739901017A1Q38356102-E92EA644-FDE7-4D54-AB65-C942F249B3ACQ38671355-6FB7B9B9-FC7C-4394-9BE0-DFBA888E950CQ38730792-2A9CA68A-98B1-41F0-8098-3CA26DAF2048Q38731861-8852CA5C-52BA-4D2E-A682-951E163BD001Q38745926-47066301-E3BD-4B53-A9E4-C4E779461FB9Q38920663-24D0BE57-A422-4F72-B4C3-7DC974E64524Q39173878-32B7439C-CE23-4454-A136-44579F54B3C6Q39205202-9227DA6B-E7D6-4739-9BC3-875BE7D4AEC7Q41044524-815153B5-C713-4AA8-AAE7-F006A6EF2FE9Q41084075-872410FC-138D-4624-87D8-063DE3C16E32Q41496288-BAD5A334-48AD-4DA0-A159-63F08E697619Q47203358-16C15278-BF00-4240-9A27-FC8829307854Q47663303-4EFE94D9-2B3E-4109-A0AD-FBA6FB049797Q48205685-11CD293C-C00E-4833-BB8C-205D0528FBDDQ49056452-52AF94B4-AC38-4146-9C7E-FDC3712D6202Q51465026-EA52B093-D506-4D45-B40A-8EA8144B476AQ55252859-09228657-8D26-43C1-9E7C-B99E3160F0E6Q55279322-4E8B283D-4B7C-498A-9F95-A86E3317617AQ58725140-43F53963-014D-4E43-816E-F79F30BE5FC7
P2860
Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 07 October 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Prostate-specific antigen chan ...... with second-line chemotherapy
@en
Prostate-specific antigen chan ...... with second-line chemotherapy.
@nl
type
label
Prostate-specific antigen chan ...... with second-line chemotherapy
@en
Prostate-specific antigen chan ...... with second-line chemotherapy.
@nl
prefLabel
Prostate-specific antigen chan ...... with second-line chemotherapy
@en
Prostate-specific antigen chan ...... with second-line chemotherapy.
@nl
P2093
P2860
P356
P1476
Prostate-specific antigen chan ...... with second-line chemotherapy
@en
P2093
Andrew J Armstrong
Chen-Yen Lin
Ellen Kaplan
Eric J Small
Johann de Bono
Nicole C Solomon
Oliver Sartor
P2860
P304
P356
10.1200/JCO.2013.50.3201
P407
P50
P577
2013-10-07T00:00:00Z